| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6242348 | Respiratory Medicine | 2014 | 8 Pages |
Abstract
HS identified azithromycin refractory patients significantly earlier than OS, possibly facilitating aggressive treatment escalation that may improve long-term outcome. Treatment response to azithromycin should be assessed 4 weeks after initiation. Responders demonstrated best survival, with even transient response conferring benefit. Macrolide-refractory BOS carried the worst prognosis.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Claudia de Wall, Dettmer Sabine, Warnecke Gregor, Greer Mark, Haverich Axel, Fuehner Thomas, Welte Tobias, Gottlieb Jens,